首页> 外文期刊>Case Reports in Rheumatology >Relapsing Polychondritis in a Patient with Ankylosing Spondylitis Using Etanercept
【24h】

Relapsing Polychondritis in a Patient with Ankylosing Spondylitis Using Etanercept

机译:使用依那西普的强直性脊柱炎患者复发性软骨炎

获取原文
           

摘要

Relapsing polychondritis (RP) is an autoimmune disease characterized by recurrent episodes of inflammation and progressive destruction of cartilaginous tissues, especially of the ears, nose, joints, and tracheobronchial tree. Its etiology is not well understood, but some studies have linked its pathophysiology with autoimmune disease and autoantibody production. We described a case of a 46-year-old male patient with ankylosing spondylitis who developed RP after the use of etanercept. Few similar cases have been described in the literature. However, they show a possible association between the use of biological inhibitors of tumor necrosis factor (anti-TNFα), which potentially produces autoantibodies, and the development of RP. The treatment was based on data in the literature and included the cessation of biological therapy and the addition of corticosteroids with substantial improvement.
机译:复发性多发性软骨炎(RP)是一种自身免疫性疾病,其特征在于炎症反复发作和软骨组织,尤其是耳朵,鼻子,关节和气管支气管树的软骨组织进行性破坏。其病因尚不十分清楚,但一些研究已将其病理生理与自身免疫性疾病和自身抗体产生联系起来。我们描述了一例46岁的男性强直性脊柱炎患者,在使用依那西普后出现RP。文献中很少描述类似的情况。但是,它们显示了使用可能产生自身抗体的肿瘤坏死因子(抗TNFα)生物抑制剂与RP的发展之间可能存在关联。该治疗基于文献中的数据,包括停止生物治疗和添加皮质类固醇激素有实质性改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号